Currently Viewing:
Newsroom
Currently Reading
Greater Symptom Burden Associated With Medical Disability Leave in Patients With MPNs
March 16, 2019 – Samantha DiGrande
Study Tracks Myotonic Dystrophy Progression in 5-Year Follow-up
March 09, 2019 – Allison Inserro
Fedratinib Earns Priority Review Status for Myelofibrosis From FDA
March 07, 2019 – Samantha DiGrande
CHMP Recommends First Treatment of FCS for Marketing Approval
March 02, 2019 – Samantha DiGrande
5 Things About Rare Disease
March 02, 2019 – Allison Inserro
Liver Biopsies Can Assist With Determining Future Status of Ruxolitinib Therapies
February 23, 2019 – Allison Inserro
Study Finds 74% Long-Term Survival Rate for Patients With Myelofibrosis
February 22, 2019 – Samantha DiGrande
A Tale of Drug Company Collaboration on a Rare Disease
February 14, 2019 – Mary Caffrey
FDA Approves the First Drug Specifically Indicated for aTTP
February 11, 2019 – Kelly Davio

Greater Symptom Burden Associated With Medical Disability Leave in Patients With MPNs

Samantha DiGrande
In a recent survey-based study, researchers analyzed the relationship between symptom burden and incidence of medical disability leave (MDL) among patients with myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia.
In a recent survey-based study, researchers analyzed the relationship between symptom burden and incidence of medical disability leave (MDL) among patients with myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. The results were published in Annals of Hematology.

Commonly experienced symptoms in patients with MPNs include fatigue, early satiety, inactivity, night sweats, bone pain, and problems with concentration. Adverse effects associated with MPNs can lead to a burden on patients’ ability to work or their employment status.

Of the 904 patients who participated in the Living with MPNs survey conducted by the study authors, 592 were employed at the time of MPN diagnosis. Among employed patients, 147 (24.8%) reported going on at least 1 MDL because of their MPN, and 293 (49.5%) reported no employment changes resulting from their MPN. The remaining 152 employed patients (25.7%) reported other non–MDL-related changes in employment status (early retirement, work hour reduction) and therefore were excluded from the remainder of the analysis.

Researchers also determined that among patients who took MDL, most (62.6%) did not return to work. Nearly half of all patients who took MDL (46.3%) reported receiving Social Security benefits while on MDL. Additionally, although most patients (85.5%) who returned to work following MDL reported receiving a similar salary to that received before the leave, 10.9% reported a decrease in salary after returning to work.

The study authors found that patients who took MDL were more likely than those who did not to report functional impairment across physical, mental, and social domains, such as difficulty sleeping, feeling depressed, and difficulty remembering, among others.

Patients with a history of thrombotic events were more than 50% more likely to have taken MDL compared with patients without such a history. Researchers recommended that “future studies should explore whether effective prevention of [thrombotic events] and management of MPN-related symptoms influences the need for forced medical leave among patients with high symptom burden.”

Reference

Yu J, Paranagama D, Geyer H, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey [published online January 29, 2019]. Ann Hematol. doi: 10.1007/s00277-019-03610-4.

Related Articles

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy
New Predictive Model Developed for Leukemic Transformation in Primary Myelofibrosis
Future of Therapy and Final Thoughts on Myelofibrosis
Study Finds 74% Long-Term Survival Rate for Patients With Myelofibrosis
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up